Krystal Biotech CEO Krishnan Krish S sold 25,000 shares at prices ranging from $354.54 to $366.56 per share. After the transactions, he owned 1,347,543 shares, giving investors a specific view of his remaining ownership in the biotechnology company following the reported insider sale.
Key Highlights
- The transactions took place on Sep. 4, 2026.
- Krishnan Krish S held 1,347,543 shares after the transactions.
- Krishnan Suma, President of R&D, was also identified as selling 25,000 shares at the stated price range.
Krystal Biotech, Inc. (NASDAQ: KRYS) President and CEO Krishnan Krish S sold 25,000 shares at prices ranging from $354.54 to $366.56 per share. The transactions occurred on Sep. 4, 2026.
Krystal Biotech Sale Details
The reported sales were recorded under SEC transaction code S. The filing reports prices ranging from $354.54 to $366.56 per share across the transactions. The transaction details identify Krishnan Suma, the company’s President of R&D, as also selling 25,000 shares across the stated price range.
Remaining Insider Ownership
Krishnan Krish S’s post-transaction holding was 1,347,543 shares. That figure represents his ownership after the reported sales.
FAQs
Q: How many Krystal Biotech shares did CEO Krishnan Krish S sell?
A: Krystal Biotech CEO Krishnan Krish S sold 25,000 shares. The transactions were completed at prices ranging from $354.54 to $366.56 per share.
Q: How many Krystal Biotech shares did Krishnan Krish S own after the sale?
A: Following the reported transactions, he owned 1,347,543 Krystal Biotech shares. The filing identifies Krishnan Krish S as the company’s President and CEO.
Q: Did another Krystal Biotech executive sell shares?
A: Krishnan Suma, Krystal Biotech’s President of R&D, was also identified as selling 25,000 shares. The stated prices ranged from $354.54 to $366.56 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.